Clinical trials that have emerged from Bernards laboratory research:
A total of 14 clinical trials (including two global phase 3 studies) have emerged from my research, highlighting the potential societal benefit of my research:
NCT01719380: Encorafenib and cetuximab with or without BYL719 BRAF mutant metastatic CRC.
NCT01750918: Dabrafenib and trametinib plus panitumumab in BRAF mutant metastatic CRC.
NCT01791309: Vemurafenib and panitumumab in BRAF mutant metastatic CRC.
NCT02039336: PD-0325901 and dacomitinib in advanced KRAS mutant cancers.
NCT02230553: Trametinib and lapatinib in advanced KRAS mutant cancers.
NCT02450656: Selumetinib and afatinib in advanced KRAS mutant cancers.
NCT02164916: Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant
Metastatic Colorectal Cancer.
NCT02928224: BEACON: (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-
mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial).
NCT02836548: HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced
Melanoma.
NCT00433589: Genetic Testing or Clinical Assessment in Determining the Need for
Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes
(MINDACT).
NCT03147040: "AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular
Breast Cancer (GELATO)"
NCT02982694: Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy
Resistant, MSI-like, Colorectal Cancer
NCT03470350: Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated
Colorectal Cancer
NCT03482362: Vinorelbine in Advanced BRAF-like Colon Cancer.
Trial numbers 1, 2, 3, 7 and 8 are based on publication:
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A. & Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103, (2012).
Trials 4, 5 and 6 are based on publication:
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., Schlicker, A., Wessels, L.F.A., Smit, E.F., Thunnissen, E., Halonen, P., Lieftink, C., Beijersbergen, R.L., Di Nicolantonio, F., Bardelli, A Trusolino, L., and Bernards, R. (2014). Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7, 86-93.
Trial 9 is based on manuscript:
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Zevenhoven, J., de Vries, T., Horlings, H., Nuijen, B., Beijnen, J.H., Schellens, J.H.M. and Bernards, R. (2018). An acquired vulnerability of drug resistant melanoma with therapeutic potential. Cell, 173, 1413-1425.
Trial 10 is based on manuscript:
van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H. & Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999- 2009.
Trial 11 is based on manuscript:
Michaut, M., Chin, S-F., Majewski, I., Severson, T.M., Bismeijer, T, de Koning, L., Peeters, J.K., Schouten, P.C., Rueda, O.M., Bosma, A.J., Tarrant, F., Fan, Y., He, B., Xue, Z., Mittempergher, L., Kluin, R., Heijmans, J., Snel, M., Pereira, B., Schlicker, A., Provenzano, E., Raza Ali, H., Gaber, A., O’Hurley, G., Sammut, S.J., Bardwell, H.A., Barbet, A.S., Bard, F., Lecerf, C., Vis, D.J., Benes, C.H., McDermott, U., Garnett, M.J., Simon, I.M., Jirström, K., Dubois, T., Linn, S., Gallagher, W.M., Wessels, L.F.A., Caldas, C., & Bernards, R (2016). Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep.6, 18517.
Trial 12 is based on manuscript:
Tian, S., Roepman, P., Popovici, V., Michaut, M., Majewski, I., Salazar, R., Santos, C., Rosenberg, R., Nitsche, U., Mesker, W.E., Bruin, S., Tejpar, S., Delorenzi, M., Bernards, R., and Simon, I. (2012). A robust genomic signature for detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J. Pathol. 228, 586-595.
Trial 13 is based on manuscript:
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., Groenendijk, F.H., Mittempergher, L., Nijkamp, W., Neefjes, J., Salazar, R., ten Dijke, P., Uramoto, H., Tanaka, F., Beijersbergen, R.L., Wessels, L. F. A., and Bernards, R. (2012). MED12 controls the response to multiple targeted cancer drugs through direct regulation of TGF beta receptor signaling. Cell 151, 937-950.
Trial 14 is based on manuscript:
Vecchione, L., Gambino, V., Raaijmakers, J., Schlicker, A., Fumagalli, A., Russo, M., Villanueva, A., Beerling, E., Bartolini, A., Mollevi, D.G., El-Murr, N., Chiron, M., Calvet, L., Nicolazzi, C., Combeau, C., Henry, C., Simon, I.M., Tian, S., in ‘t Veld, S., D’ario, G., Mainardi, S., Beijersbergen, R.L., Lieftink, C., Rumpf-Kienzl, C., Delorenzi, M., Wessels, L., Salazar, R., Di Nicolantonio, F., Bardelli, A., van Rheenen, J., Medema, R., Tejpar, S., and Bernards, R. (2016). A vulnerability of a subset of colon cancers with potential clinical utility. Cell, 165, 317-330.